The FDA on Thursday granted accelerated approval to Amgen’s bispecific T cell engager tarlatamab in small cell lung cancer, an aggressive disease that makes up roughly 10% to 15% of lung cancer cases.
It’s the first bispecific T cell engager to be approved for a major solid tumor, according to Amgen. The FDA approved the treatment for patients with extensive-stage small cell lung cancer whose disease progressed despite chemotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.